Prophylactic treatment for delayed chemotherapy-induced XXXX after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials.

@entity9766 @entity390 @entity8253 @entity391 @entity786 @entity619 @entity6303 @entity7274 @entity1037 @entity1209
PURPOSE: Delayed chemotherapy-induced @entity1209 (CINV) remains an important adverse effect of moderately emetogenic chemotherapy not containing @entity8253 and @entity786 (non-AC MEC). In this review, we summarize current literature to update recommendations for delayed @entity1209 after non-AC MEC. METHODS: We conducted a systematic search in PubMed and conference proceedings from ASCO, ESMO, and MASCC. Included randomized controlled trials (RCTs) aimed to prospectively evaluate the efficacy of two or more antiemetic strategies in the prevention of delayed CINV after the administration of non-AC MEC. At least one of the following endpoints was used: complete response, complete control, no @entity390 , no @entity391 , and/or no use of rescue medication. RESULTS: Our search provided 247 publications. Nine met the predefined criteria. Included RCTs reported outcomes on @entity7274 , aprepitant, casopitant, netupitant/ @entity7274 (NEPA), @entity1037 , and @entity6303 . CONCLUSIONS: Superiority of @entity7274 over first-generation 5-HT3 receptor antagonists for the prevention of acute and delayed CINV after non-AC MEC has not been proven. The addition of an @entity9766 antagonist to first-generation 5-HT3 receptor antagonists does not significantly improve the incidence of delayed CINV after non-AC MEC. The efficacy of a single-day regimen of @entity619 with @entity7274 is non-inferior to multiday @entity619 . NEPA, @entity1037 , and @entity6303 show highly effective complete response (CR) rates.
